Rany Condos, MD
Pulmonary Disease · Astoria, NYNPI 1053302117
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,365 of the $118,878 with a category attached, or 65.1%. Boehringer Ingelheim accounts for 60.8% of it on its own, with 12 other manufacturers making up the rest. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $612.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$72K
- Vertex$29K
- Genentech USA, Inc.$16K
- AstraZeneca$445
- Insmed, Inc.$434
- Gilead$223
- plus $375 from 7 others
Across 68 payments — averaging $3533.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$104K
- Boehringer Ingelheim$70K
- United Therapeutics Corporation$60K
- Boehringer Ingelheim International GmbH$7K
What the payments were for
- Consulting fees$37,20331%
- Speaking & faculty fees$77,36565%
- Food & beverage$4,0903%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 61 | $72,296 |
| Vertex | 55 | $29,227 |
| Genentech USA, Inc. | 12 | $15,879 |
| AstraZeneca | 26 | $445 |
| Insmed, Inc. | 17 | $434 |
| Gilead | 6 | $223 |
| GSK | 8 | $155 |
| Mallinckrodt Hospital Products Inc. | 2 | $68 |
| Baxter Healthcare | 1 | $49 |
| Philips North America LLC | 3 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Electromed, Inc. | 1 | $23 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,878 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 64 | $749,448 |
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 13 | $338,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $85,887 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $32,039 |
| EliquisApixaban | 14 | $22,663 |
| XareltoRivaroxaban | 20 | $21,569 |
| Pirfenidone | 32 | $21,331 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $13,121 |
| Spiriva RespimatTiotropium Bromide | 17 | $12,641 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $9,637 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $7,449 |
| Theo-24Theophylline Anhydrous | 14 | $2,654 |
| Diclofenac Sodium | 12 | $1,992 |
| Ventolin HfaAlbuterol Sulfate | 11 | $1,757 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $72,296 | $771,725102 claims |
| VertexTrikafta | $29,227 | $338,19613 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $155 | $138,497159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Astoria
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.